The DIA 2012 48th Annual Meeting will be held June 24-28 at the Pennsylvania Convention Center.
Philadelphia Mayor Michael Nutter to open DIA 2012 48th Annual Meeting. (Photo: Business Wire)
The DIA Annual Meeting is the premier event for the life sciences industry, as 7,000 professionals from around the world come together to share best practices for improving the global health care landscape. By bringing together all stakeholders—industry, government, academia, and patient organizations—we are helping to shape the future of the industry.
The DIA 2012 48th Annual Meeting features:
- Welcome Address by Philadelphia Mayor Michael Nutter
- Keynote Address by Dean Kamen, Founder and President, DEKA Research & Development Corporation
- 280+ sessions and 20 preconference tutorials
- Global regulatory agency town halls
- Patient Advocate Fellowship Program
- Student and professional poster presentations
- Executive sessions
- 500+ exhibiting companies
Thought leaders in attendance. The participation of influential thought leaders provides a unique opportunity to collaborate with top professionals working here and abroad. People like:
- Margaret A. Hamburg, MD, Commissioner, FDA
- Paul Glover, Health Canada
- Freda Lewis-Hall, Chief Medical Officer and Senior Vice President, Pfizer Inc
- Susan McCune, Deputy Director, Office of Translational Sciences, CDER, FDA
- Jeffrey P. McMullen, President and CEO, PharmaNet/i3, an inVentiv Health Company
- Douglas J. Peddicord, Executive Director, Association of Clinical Research Organizations
- Guido Rasi, Executive Director, European Medicines Agency
- Josef von Rickenbach, Chairman and CEO, PAREXEL International
- William J. Sharbaugh, Chief Operating Officer, PPD
- Paula Brown Stafford, President, Clinical Development, Quintiles
- Thomas P. Stossel, MD, Director, Translational Medicine Unit and Center for Medical Innovation Brigham & Women's Hospital
- John Watson, Chief Commercial Officer, Corporate Senior Vice President, Covance Inc.
Content-driven agenda. DIA 2012 is packed with 280 sessions across 22 disciplines, including several half- and full-day sessions created in partnership with leading health organizations such as the Bill & Melinda Gates Foundation and The Pew Charitable Trusts.
Hot-topic sessions. These presentations—reflecting the conference's theme of "Collaborate to Innovate"—showcase expertise across the legislative, regulatory, and industry realms:
- Panel on the Physician Payments Sunshine Act. Experts will discuss the potential ramifications the implementation of this disclosure law will have on public health, medicine, and clinical research.
- Directors on devices. Several former directors of the influential Center for Devices and Radiological Health—a regulator of US medical devices within the US Food and Administration (FDA)—will talk product evolution and regulation.
- Views from the Heads of Health Canada, the European Medicines Agency, and the US FDA. After working to harmonize technical requirements under the ICH, establishing confidentiality arrangements, collaborating on inspection pilots, exchanging working level scientific and regulatory policies, procedures, and reports, and implementing technical level "clusters" of agency reviewers, leaders from the US FDA, EMA, and Health Canada discuss the challenges and next steps in 21st century regulatory cooperation.
- Drug Shortages 2012: Rewind, Repeat, Recovery. This session focuses on characterizing the current issues surrounding shortages of medically necessary drug products. Speakers from FDA and industry present initiatives underway and strategies under consideration for effectively dealing with, and mitigating, existing drug shortage situations, and for preventing new drug shortages from developing.
- Collaboration call to action. Partnerships can advance innovation in drug development, but they are complex. DIA 2012 assembles FDA's Susan McCune, Deputy Director, Office of Translational Sciences, CDER, Pfizer's Dr. Freda Lewis-Hall, and FasterCures' Margaret Anderson to help us move away from stovepipes and toward meta-collaborations.
"The Philadelphia area is already on the map as a premier center for life sciences education, research and innovation. The region is within reach of 80 percent of the world's largest pharmaceutical firms and home to renowned medical schools and hospitals," says DIA Worldwide Executive Director Paul Pomerantz. "The close proximity of these enterprises allows us to support science and technology entrepreneurs, commercialize new products and treatments, and educate the next generation of life science innovators."
ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. www.diahome.org.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50318650&lang=en
Contacts:
DIA
Joe Krasowski, 215-293-5812
Joe.Krasowski@diahome.org
